GlaxoSmithKline exercises option for cancer drug
As part of its June 1996 agreement with GSK, Human Genome Sciences granted a 50/50 co-development and co-promotion option to GSK for certain human therapeutic products that complete
China-based Biocytogen Pharmaceuticals has entered a non-exclusive licensing agreement with Qilu Pharmaceutical for a fully human VHH antibody molecule.
Products developed under the collaboration may include either monoclonal antibodies or antibodies linked to potent cell-killing payloads utilizing Seattle Genetics’ antibody-drug-conjugate (ADC) technology. “We’re pleased that Seattle Genetics